The compounds display large thermal hysteresis.
These compounds display activity in the low nanomolar range.
Some of the compounds display aggregation-induced emission characteristics.
Two compounds display different thermal and magnetic behaviors.
In general, these compounds display 2D similarities below those of compounds cross-reactive with the immunoassays.
Furthermore, both 177Lu-labeled compounds display an enhanced lipophilicity compared to their corresponding 68Ga analogs.
These compounds display EC50 values in the picomolar range with a large therapeutic index (>106).
Furthermore, most of these new nicotinic compounds display little, if any, agonist activities at α3β4 nAChR.
Most of these compounds display antibacterial activity against sensitive and resistant Staphylococcus aureus.
All the described compounds display unique molecular architectures, which have been determined by X-ray measurements.
These compounds display excellent oral bioavailability and good overall pharmacokinetic profiles in preclinical species.
